Clinical Trial Update: Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating low-dose IL-2 to induce regulatory T cells in various autoimmune and inflammatory diseases; trial completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Autoimmune Hepatitis
• Behçet Disease
• Crohn Disease
• Gougerot-sjögren Syndrome
• Idiopathic Thrombocytopenic Purpura
• Psoriasis
• Rheumatoid Arthritis
• Sclerosing Cholangitis
• Systemic Lupus Erythematosus
• Systemic Sclerosis
• Takayasu Disease
• Ulcerative Colitis
• Wegener Granulomatosis

Drugs mentioned

• Interleukin-2 (low-dose IL-2) (interleukin-2)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Rheumatoid Arthritis, Ankylosing Spondylitis | Phase 2 | Status: COMPLETED